GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Fast Facts

20 Years of Publications

  • 2015 (359)
  • 2014 (320)
  • 2013 (281)
  • 2012 (267)
  • 2011 (225)
  • 2010 (204)
  • 2009 (161)
  • 2008 (146)
  • 2007 (149)
  • 2006 (121)
  • 2005 (134)
  • 2004 (115)
  • 2003 (106)
  • 2002 (78)
  • 2001 (75)
  • 2000 (54)
  • 1999 (45)
  • 1998 (33)
  • 1997 (34)
  • 1996 (36)
  • 1995 (19)
  • 1994 (29)
  • 1993 (26)

Highlights of PHRI Studies Supporting Regulatory Approvals Around the World

Study Name Drug Indication
HOPE Ramipril Secondary Prevention
RESOLVD Candesartan
Metoprolol CR
Heart Failure
Heart Failure
OASIS-4 Clopidogrel Unstable Angina/Non-ST Elevation MI
OASIS-5 Fondaparinux Unstable Angina/Non-ST Elevation MI
OASIS-6 Fondaparinux ST Elevation MI
ONTARGET/TRANSCEND Telmisartan Prevention of Cardiovascular Disease
RE-LY Dabigatran Prevention of Stroke in Atrial Fibrilation
AVERROES Apixaban Prevention of Stroke in Atrial Fibrilation

6 Continents, 101 Countries

about-mission-statement-map

Africa (15)

Benin Republic, Botswana, Cameroon, Ghana, Kenya, Mozambique, Nigeria, Seychelles, Sierra Leone, South Africa, Sudan, Tanzania, Uganda, Zimbabwe.

Asia (25)

Bahrain, Bangladesh, China, Hong Kong, India, Indonesia, Iran, Israel, Japan, Kuwait, Malaysia, Nepal, Oman, Pakistan, Philippines, Qatar, Russia, Saudi Arabia, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Turkey, United Arab Emirates.

Europe (29)

Austria, Belarus, Bulgaria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom.

Oceania (2)

Australia, New Zealand

N. America (7)

Bermuda, Canada, Cuba, El Salvador, Guatemala, Mexico, United States.

S. America (8)

Argentina, Brazil, Chile, Colombia, Ecuador, Peru, Uruguay, Venezuela.